Longevity research asks why organisms age, why some people remain healthy longer than others and whether disease-free years can be extended. This is a legitimate scientific field. The commercial anti-ageing industry often goes much further, presenting early laboratory findings as evidence that ageing is close to being slowed, reversed or cured.
Lifespan and healthspan are different
Living longer is not automatically beneficial if disability and illness are merely prolonged. Much of the serious research focuses on healthspan: delaying multiple age-related diseases and preserving function. That goal is more useful than treating the maximum recorded age as the main measure of success.
Animal results do not directly predict human outcomes
Calorie restriction, genetic changes and drugs can extend lifespan in worms, flies and mice. Translation is difficult because species age differently and laboratory animals live in controlled conditions. An intervention that changes median mouse lifespan may have no meaningful benefit—or unacceptable side effects—in humans.
Biomarkers are not proof of rejuvenation
Epigenetic clocks and other biological-age measures can be useful research tools, but changing a biomarker does not necessarily mean that a person will live longer or avoid disease. A test may correlate with ageing while still being unsuitable as a surrogate endpoint for a treatment.
Senolytics remain experimental
Senescent cells are associated with ageing and disease, and removing them has produced interesting animal results. Human studies are still early. Senescent cells also have useful roles in wound healing and tumour suppression, so indiscriminate removal may create harm.
Metformin, rapamycin and supplements
Existing medicines are widely discussed as longevity drugs, but observational evidence and mechanistic plausibility are not enough to establish broad preventive use. Dose, immune effects, metabolic consequences and interactions matter. Supplements sold with anti-ageing language often have weaker evidence and poorer quality control than their marketing suggests.
Partial cellular reprogramming
Reprogramming cells toward a younger state is scientifically striking, but uncontrolled reprogramming can erase cell identity or promote tumours. Moving from cell culture or animals to safe systemic treatment in humans is a major challenge, not a routine next step.
The commercial incentive to overpromise
People fear ageing and disease, creating a market for expensive tests, clinics and off-label treatments. Companies may sell access to uncertainty while presenting participation as empowerment. Informed consent is weakened when the evidence, risks and financial interests are not stated clearly.
Inequality and population health
The largest gains in healthy lifespan still come from public health, vaccination, safer work, clean air, stable housing, exercise and effective treatment of common disease. A future in which wealthy people buy marginal biological advantages while basic care remains unequal would not represent broad progress.
A credible research agenda
Ageing biology may lead to treatments that delay particular diseases or preserve function. Claims should be based on controlled human outcomes, not a changed clock, a mouse lifespan or a founder’s forecast. The goal should be healthier lives, not an industry built around the promise of escaping human limits.